MedPath

FDA Approves Nypozi (filgrastim-txid) as Biosimilar to Neupogen

• The FDA has approved Nypozi (filgrastim-txid), a biosimilar to Amgen's Neupogen, marking a significant milestone for Tanvex BioPharma, transitioning it into a commercial entity. • Nypozi is indicated to reduce infection incidence, particularly febrile neutropenia, in non-myeloid malignancy patients undergoing myelosuppressive anticancer treatments. • Filgrastim products, including Neupogen and biosimilars, generated over $400 million in sales in the U.S. in the 12 months leading up to March 2024. • Tanvex BioPharma launched Nypozi in Canada in January 2024, expanding its market presence prior to the U.S. FDA approval.

The U.S. Food and Drug Administration (FDA) has approved Nypozi (filgrastim-txid), a biosimilar to Amgen's Neupogen, as announced by Tanvex BioPharma, Inc. on June 28, 2024. This approval marks a pivotal moment for Tanvex, transitioning the company from a clinical and developmental stage to a commercial entity in the U.S.

Clinical Indication and Impact

Nypozi is indicated to decrease the incidence of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs. These drugs are often associated with a significant risk of severe neutropenia accompanied by fever, a condition that Nypozi aims to mitigate. The biosimilar's approval offers a potentially more cost-effective alternative to Neupogen, expanding access to this essential supportive care medication.

Market Context

According to IQVIA data, the market for filgrastim products in the United States exceeded $400 million in sales for the 12 months ending in March 2024. Tanvex BioPharma has already launched Nypozi in Canada in January 2024, establishing a market presence prior to the U.S. approval. This positions Tanvex to compete effectively in the biosimilar market, offering a lower-cost alternative to the reference product.

Tanvex BioPharma's Perspective

"This milestone has moved the company beyond being a clinical/developmental stage company to a commercial company in the U.S.," stated Henry Chen, Chairman and CEO of Tanvex BioPharma, Inc. The FDA's decision underscores the potential for biosimilars to provide cost-effective treatment options while maintaining comparable safety and efficacy to their reference products.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Celgene’s Multiple Myeloma Orphan Drug Gets FDA Approval

The FDA has approved Celgene's Pomalyst, a treatment for multiple myeloma, under its accelerated approval program. Pomalyst is intended for patients who have not responded to other treatments, offering a new option for those with this rare condition.

FDA Approves Subcutaneous Opdivo Qvantig for Multiple Solid Tumors

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous use, offering a new administration option for various solid tumors.
The approval was based on the CheckMate-67T trial, demonstrating non-inferior pharmacokinetic exposures and comparable safety to intravenous Opdivo.

FDA Approves Novo Nordisk's Esperoct for Hemophilia A

The FDA has approved Novo Nordisk's Esperoct (turoctocog alfa pegol) for routine prophylaxis and on-demand treatment of bleeding episodes in adults and children with hemophilia A.
Esperoct is a novel glycoPEGylated factor VIII (FVIII) replacement therapy with an extended half-life, offering potentially less frequent dosing compared to standard FVIII products.

FDA Approves Hympavzi (marstacimab-hncq) as Novel Treatment for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a novel monoclonal antibody, for hemophilia A and B in patients 12 years and older.
Hympavzi offers a new mechanism by reducing tissue factor pathway inhibitor, enhancing thrombin production to facilitate blood clotting.

FDA Approves Perioperative Nivolumab for Resectable NSCLC Without EGFR or ALK Mutations

The FDA approved nivolumab with platinum-doublet chemotherapy as neoadjuvant treatment, followed by nivolumab as adjuvant treatment for resectable NSCLC.
The approval is specifically for patients without EGFR mutations or ALK rearrangements, based on the CheckMate-77T trial results.

FDA Approves Nymalize in Prefilled ENFit Syringes for Subarachnoid Hemorrhage

The FDA has approved Nymalize (nimodipine) oral solution in prefilled ENFit syringes, offering a potentially more secure drug administration method.
Nymalize is indicated for improving neurological outcomes by reducing ischemic deficits in adults with subarachnoid hemorrhage from ruptured intracranial aneurysms.

FDA Approves Incyte and Syndax's Niktimvo for Chronic Graft-versus-Host Disease

The FDA has approved Niktimvo, developed by Incyte and Syndax Pharmaceuticals, for treating chronic graft-versus-host disease (cGVHD).
Niktimvo is intended for adult and pediatric patients (weighing at least 88.2 pounds) who have failed at least two prior systemic therapies.

FDA Approves Galderma's Nemolizumab (Nemluvio) for Prurigo Nodularis

The FDA has approved Nemluvio (nemolizumab) as the first monoclonal antibody inhibiting IL-31 signaling for treating prurigo nodularis in adults.
Clinical trials (OLYMPIA 1 and 2) showed significant improvements in itch and skin nodules, with some patients experiencing relief as early as Week 4.

FDA Approves PEMFEXY® Combination Therapy for Metastatic Non-Small Cell Lung Cancer

Eagle Pharmaceuticals' PEMFEXY® gains FDA approval for use with pembrolizumab and platinum chemotherapy in metastatic non-squamous NSCLC patients without EGFR or ALK aberrations.
PEMFEXY®, a ready-to-dilute liquid formulation, now holds the same indications as ALIMTA®, offering advantages like eliminating reconstitution steps.

FDA Approves Fylnetra, Fifth Biosimilar of Neulasta, for Febrile Neutropenia

The FDA has approved Fylnetra (pegfilgrastim-pbbk), a biosimilar referencing Neulasta, developed by Amneal Pharmaceuticals and Kashiv Biosciences.
Fylnetra is indicated to treat or prevent febrile neutropenia in cancer patients undergoing chemotherapy, addressing a critical need in supportive cancer care.

Reference News

[1]
FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen
drugs.com · Jul 1, 2024

FDA approves Nypozi (filgrastim-txid), a biosimilar to Neupogen, indicated to decrease the incidence of infection in pat...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy